Development

Articles

The companies will work to discover and develop RNA-targeting small-molecule therapeutics for difficult-to-address indications.

Evotec and Takeda Enter into Multi-RNA Target Alliance

Jennifer Markarian is a contributing editor for 

Continuus Pharmaceuticals is building the first GMP facility using integrated continuous manufacturing technology for end-to-end production of small-molecule APIs and finished dosage forms.

Building Up End-to-End Continuous Manufacturing

USP is collaborating with Phlow to build a new lab that will develop test methods and standards to facilitate broader adoption of continuous manufacturing. 

New Lab Will Develop Standards for Continuous Manufacturing 

FDA moves recommended timeline for API and drug manufacturers to assess impurity risks to March 31, 2021.

Nitrosamine Risk Assessment Date Extended

The deal expands Wavelength’s drug substance manufacturing footprint and its API CDMO business.

Wavelength Pharmaceuticals Acquires Vanamali Organics

The increased services will work in conjunction with the site’s SimpliFiH Solutions first-in-human services, which includes phase-appropriate drug substance and drug product development and manufacturing.

Lonza to Expand its Small Molecule Services at Oregon Site

Eric Sanchez is a senior consultant of Integra Continuous Manufacturing Systems with a special focus on the implementation of continuous manufacturing methods. He joined the firm after a successful 31-year career with Janssen Pharmaceuticals.

Fernando J. Muzzio, PhD, is distinguished professor of the School of Engineering at Rutgers, The State University of New Jersey, Piscataway, NJ 08855. Dr. Muzzio is a member of 

 editorial advisory board and President of Integra Continuous Manufacturing Systems.

Advanced manufacturing technologies are available, but challenges need to be addressed.

 Reshoring Pharmaceutical Manufacturing to the US: Can We Do It?

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Operator, caregiver, and patient safety are at the forefront when selecting the best options and dosage forms.

HPAPI Complexity Prompts New Delivery Mechanisms

The expansion will be designed to meet the growing demand for small molecule drug substance development and manufacturing.

Cambrex to Invest More than $50 Million into Iowa Site Expansion

Biological and analytical advances enable modern fermentation processes to deliver safe and effective next-generation medicines.

API Synthesis and Manufacturing, Small Molecule